Rova T Crash And Burn

Quote

Hows that $10B stock buyback working Rick ? You wasted Corporate Tax Cut already ?
Trump was a damn fool to let you and other Corporate LEECHES play out our Country.
Rick, you're a fool to think investors aren't aware of your despicable game.

INDEXDJX: .DJI
24,618.20 UP +156.50 (0.64%)

AbbVie Inc
NYSE: ABBV
$94.40 USD DOWN −1.15 (1.20%)
 



Lordy Lordy, pipeline crashing, stock crashing, stock buyback a flop and waste of Tax $$ creating NO jobs. A slap in the face to taxpayers. Now your degree less 12th grade high school graduate CEO makes another absurd desperate move and gives a 4 year upfront license agreement with Calibr for a CAR-T platform? T-cell therapies are showing little to no progress. ROVA T is DOA, and Rick tries to bail out the sinking ship with a Dixie cup. Hah Hah Hah

The Street sentiment tells all
Abbv
$93.19 DOWN (0.33%)
 












anonymous said:
Google's sister company is Calico. Abbv Price target SLASHED to $85
Based on current stock trend, Ricks salary and incentives for 2018 will be DOWN 45%
2018 total comp will be $12M
AbbVie Inc
NYSE: ABBV
$92.12 USD DOWN−0.91 (0.98%)
Click to expand...

Who is Calico and what is their credibility? Are they a trusted financial authority?
Yahoo Finance's 1y Target Estimate id $113.62. I think they are more of a trusted source.
Nasdaq.com has ABBV at $112.
Marketwatch has ABBV at $112.86

Hmm.....
 



anonymous said:
Who is Calico and what is their credibility? Are they a trusted financial authority?
Yahoo Finance's 1y Target Estimate id $113.62. I think they are more of a trusted source.
Nasdaq.com has ABBV at $112.
Marketwatch has ABBV at $112.86

Hmm.....
Click to expand...
Calico is the real deal. Art leads that company. True visionaries. Fountain of youth regimen in development.
 



anonymous said:
Who is Calico and what is their credibility? Are they a trusted financial authority?
Yahoo Finance's 1y Target Estimate id $113.62. I think they are more of a trusted source.
Nasdaq.com has ABBV at $112.
Marketwatch has ABBV at $112.86

Hmm.....
Click to expand...

Hey chief, the average price target is $112.50 with a high estimate of $135.00. You conviently left out the LOW estimates of $78. How come ? Nice try. Looks like a sure bet the $78 is what we will see. Any vpak Numbers son ? Hah Hah So Easy to bust you.
 



anonymous said:
Calico is the real deal. Art leads that company. True visionaries. Fountain of youth regimen in development.
Click to expand...

Fountain of youth ? Hah hah hah, It's a pipe dream. Only God has the power to give eternal life.
If this fairy tale ever occurred, it would signal armageddon. Hey, maybe they could develop a condensed college course for Gonzalez, since his highest level of education attained was high school.
 






Doing some compliance research and see that ONLY $5.7M of assets held on behalf of ALL Stemcentrx employees by a multiple employer plan was transferred into the AbbVie Plan. WOW that's pocket change and doesn't seem like Stemcentrx compensated employees and it's C suite very well. Stemcentrx had big league backers including Sequoia Capital, Elon Musk and Peter Thiel's Founders Fund. Rick was suckered by the BEST.
 






Pharma's 2 Biggest Setbacks in 2018
1. AbbVie's Rova-T
In June 2016, AbbVie doled out $5.8 billion to acquire Stemcentrx for its cancer stem-cell therapy called Rova-T (rovalpituzumab tesirine) as a possible game-changing treatment for small-cell lung cancer. Immediately thereafter, analysts chimed in to name Rova-T as one of the most valuable experimental therapies in the clinic at the time. EvaluateGroup, for example, had the therapy's peak sales coming in at a staggering $8.3 billion by 2023, which would have propelled it into the top five best-selling pharma products in the world.

What a difference two years make. After posting dismal midstage trial results for third-line small-cell lung cancer last March, AbbVie revealed at the recent American Society for Clinical Oncology meeting that Rova-T's ongoing trials are showing little sign of efficacy, and poor side-effect profiles to boot. The point being that Rova-T went from a shining star to a potential complete dud in a year's time. As a result, EvaluateGroup downgraded its outlook for the drug's peak sales to a mere $193 million by 2024. That's a stunning 98% drop from where the drug stood in terms of market value back in 2017.

How did this setback impact AbbVie's valuation? Over the course of Jan. 1, 2017, to the day before Rova-T's midstage results were released in March 2018, AbbVie's shares were up by 80%. That kind of high-flying action is certainly unusual for a large-cap biotech stock, perhaps reflecting the market's enthusiasm for this key pipeline asset. In the intervening three-plus months since Rova-T's initial data release, however, AbbVie's shares have been extremely volatile, shedding nearly 7% of their value overall. That's not the end of the world, but AbbVie's upward momentum has certainly tapered off noticeably.

2. Celgene's ozanimod
Approximately three years ago, Celgene purchased Receptos for a noteworthy $7.2 billion for its experimental immunomodulatory drug ozanimod. At the time, the drug was already in human trials for both multiple sclerosis and ulcerative colitis; it had shown promise as a truly game-changing therapeutic option for these hard-to-treat conditions. Celgene thus rolled out a peak sales estimate for ozanimod of between $4 billion to $6 billion during its initial press release announcing the acquisition.

The take-home point here is that with this pricey acquisition, the blue-chip biotech appeared to have finally found its heir apparent to the aging multiple-myeloma drug Revlimid as its next flagship product.

Then the wheels fell off. Despite strong late-stage trial data showing that ozanimod was indeed a potent new therapy for relapsing multiple sclerosis, Celgene reportedly allowed the skeleton crew remaining at the Receptos facility in California to handle the drug's regulatory application with the Food and Drug Administration (FDA). At least that's what Celgene said after the drug got nailed with a refusal-to-file letter from the FDA for missing preclinical and clinical pharmacology data last February. Now the drug isn't scheduled to reach the market until perhaps late 2019.

Why is this regulatory delay such a big deal? Analysts believe that this lengthy delay could allow the drug's competitors across its various indications to catch up from a development standpoint. If so, these same analysts think that ozanimod's commercial opportunity could be slashed by a stunning 56% from peak. That's seriously bad news, especially as the company searches for a way to keep growing beyond Revlimid's eventually date with the patent cliff.

So it's not surprising that Celgene's shares dropped by as much as 25% from their 52-week highs in the months following this self-inflicted wound.
 









anonymous said:
Look at the pipeline. Cupboard bare when Humira loses patent protection. Layoffs coming as obvious that the company needs to begin to adapt to its coming reality.
Click to expand...
We don't need so many rank&file in the sales force as we currently have. We are way overstaffed with mediocre sales and layoffs are demanded to retain shareholder equity.
 






anonymous said:
According to my financial advisor, we also have a bloated corporate structure relative to some of our peer companies. At least sales people move product.
Click to expand...
Many in sales are mere shelf stockers!!

as an insider can say Corp. HQ is seriously under staffed. We are bringing in interns to help out. You are way off base. Get your facts strait !!!!
 






Check out our SG&A ratio relative to peer companies. Get your facts straight. No one in their right mind thinks AbbVie HQ is understaffed. Look at the numbers.

anonymous said:
Many in sales are mere shelf stockers!!

as an insider can say Corp. HQ is seriously under staffed. We are bringing in interns to help out. You are way off base. Get your facts strait !!!!
Click to expand...
 



Top Bottom
Back
Quote